Bridge to Life's $110M raise puts VitaSmart on a path to every U.S. transplant center

Bridge to Life, a Duluth, Georgia-based company that describes itself as a market leader in organ preservation solutions and perfusion technologies, has closed a $110 million Series C and debt financing.

The equity portion of the round was led by new investor Soleus Capital, with participation from Lauxera Capital Partners as well as Bridge to Life directors, officers, and employees. The debt financing was provided by Soleus Capital Credit Opportunities Fund.

A large share of the proceeds is earmarked for the commercial push behind VitaSmart, the company's hypothermic oxygenated perfusion system. Bridge to Life said the money will expand its field team and provide the working capital needed to reach every U.S. transplant center.

The remainder is directed at the company's new product pipeline, including a proprietary viability assessment tool, a broadening of its organ preservation portfolio, and the scaling of global operations.

The financing also reshapes Bridge to Life's balance sheet. Proceeds were used to refinance the company's credit facility with Perceptive Credit Funds, which the company said significantly reduces its outstanding leverage and lowers its interest rate — a move it tied to its evolution from an early development-stage business to a fully commercial organization.

For a company selling into transplant centers and organ procurement organizations, reach is the operative metric. Bridge to Life frames the round less as a bet on a single device than as funding for a nationwide commercial footprint, paired with pipeline work intended to extend what it can offer alongside preservation and perfusion. The viability assessment tool in development points toward a future where the company's offering covers not just keeping an organ viable in transit but evaluating it before transplant.

The combined equity and debt structure is notable: rather than relying solely on venture equity to fund the rollout, Bridge to Life split the raise between growth capital and credit, using part of the package to retire existing debt on better terms.

With the round closed, the company's immediate task is execution — building out the field organization, reaching transplant programs across the United States, and bringing the next products in its pipeline forward.